LATEST COMPANY NEWS. - Free Online Library (2024)

Link/Page Citation

Asia Times - A US-China pharma drug war in the making - 29/4/2024

US Congress has China's biotech research and drug manufacturing firms in its decoupling sights

For the complete story, see:

https://asiatimes.com/2024/04/a-us-china-pharma-drug-war-in-the-making/

Epoch Times - The CCP's "Father of Sinopharm Vaccine" was dismissed, and people are worried about the safety of the vaccine - 28/4/2024

For the Chinese language, see:

https://www.epochtimes.com/gb/24/4/28/n14235930.htm

The Diplomat - China, Fiji and the Fentanyl Scourge - 27/4/2024

Heightened geopolitical tensions are evident across numerous global pressure points at present,

For the complete story, see:

https://thediplomat.com/2024/04/china-fiji-and-the-fentanyl-scourge/

Zhang, X., Tang, S., & Fu, S.

Abstract

The purpose is to explore the relationship between innovation efficiency and industrial development in China's pharmaceutical manufacturing industry. The method is to conduct empirical research using panel data from 29 provinces in China from 2010 to 2020 based on super efficiency three-stage SBM model and semi parametric spatial lag model. The result is that the industrial development of the pharmaceutical manufacturing industry has a significant negative spatial spillover effect, with a coefficient of -0.171 in the semi parametric spatial lag model. The innovation efficiency of the pharmaceutical manufacturing industry has a non-linear impact on its industrial development,

https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4757793

The Industry

Chinese bio/pharma oncology IPOs metastasise

The number of IPO deals in China has grown consistently over the last five years where oncology has remained the top area for therapeutic companies going public in China.

Chinese-headquartered bio/pharma initial public offerings (IPOs) increased in value by 80% from 2019 to 2020, reaching $3.8B for 2020 alone, according to GlobalData's Pharma Intelligence Centre Deals Database. The number of IPO deals in China has grown consistently over the last five years where oncology has remained the top area for therapeutic companies going public in China. Since 2019, China stepped up its IPO reform by introducing a pilot registration-based system for its capital markets.

Chinese oncology therapeutic companies showed a 150% increase in the number of IPO deals from 2019 to 2020 compared to other therapy areas, as shown in Figure 1. RemeGen raised $514M for its IPO completed in November 2020, with the majority of its drug pipeline for Oncology. Jiangsu Hansoh Pharmaceutical Group remains on top with the largest IPO deal in China of $1B completed in June 2019, with its drug pipeline spanning across many of the top therapy areas. However, China still lags behind the US in number of IPOs completed from 2019 to October 2021, with the US having 5.5 times more completed IPO deals compared to China, according to GlobalData's Pharma Intelligence Center Deals Database.

In September 2021, the President of China Xi Jinping, announced plans for a new stock exchange in Beijing to provide financing for innovative small and medium-size companies. This would be similar to the Shanghai Stock Exchange Science and Technology Innovation Board (STAR) launched in July 2019, as a rival to the US Nasdaq, to encourage innovative companies to list before they have a marketed drug. However, the number of biotech companies with innovator drugs listed on the Nasdaq and New York stock exchanges is still higher than on China's Shanghai and Shenzhen exchanges.

The downturn in Chinese IPOs in 2021 was due to the Shanghai Stock Exchange remaining flat where the top companies on the SSE 50 and SSE 80 indices have been down. It remains to be seen if the number of Chinese bio/pharma companies going public may change for next year.

Source: Pharmaceutical Technology.

https://www.pharmaceutical-technology.com/comment/chinese-bio-pharma-oncology/

Leading Companies

Beijing Tongretang Co., Ltd. (SHA: 600085)

Tongrentang Group Basic Information.

China Beijing Tongrentang (Group) Co., Ltd. is a wholly state-owned company authorized by the Beijing Municipal Government to operate state-owned assets. Beijing Tongrentang was founded in 1669 and has a history of 350 years. It is a well-known old brand in the Chinese medicine industry.

In history, Tong Ren Tang once served the Qing dynasty royal medicine, after eight generations of emperors 188 years. After liberation, Tong Ren Tang actively responded to the government's call and first took the lead in achieving public-private partnerships in 1954. In July 1992, with the approval of the Beijing Municipal Government, Beijing Tongrentang Group Co., Ltd. was formally established and later restructured into a wholly state-owned Beijing Tongrentang (Group) Co., Ltd. In 1997, the group carried out a share reform and established a state-controlled Beijing Tongrentang Co., Ltd., which was listed on the Shanghai Stock Exchange. In 2000, Tongrentang Co., Ltd. "divided" some assets and established Beijing Tongrentang Technology Development Co., Ltd., which was listed in Hong Kong that year. In May 2013, Beijing TongrentangSinopharm Co., Ltd. was listed on the Hong Kong Growth Enterprise Market and became the third listed company under Tongrentang. In May 2018, it completed the transfer to the Main Board.

By the end of 2018, Tongrentang Group had more than 2,600 kinds of six major categories of products such as medicines and health foods, 36 production bases, 110 modern production lines, a national engineering center and post-doctoral research stations. The group system has a total of 2,227 retail terminals (including 149 overseas); 561 medical service terminals (including Chinese medicine hospitals and clinics) (including 80 overseas).

In recent years, Tongrentang has adhered to reform and innovation, adhered to the strategic goal of "making excellence, excellence, strength, and long-term", and formulated the development orientation of "building an internationally renowned and domestically leading health industry group with Chinese medicine as its core". Focusing on the main business, we will vigorously promote the construction of industrial bases, commercial networks and talent teams, technological innovation, and information network platforms. Tongrentang has formed seven secondary groups (including: stock group, science and technology development group, Sinopharm Group, health pharmaceutical group, commercial investment group, medicinal materials ginseng group, medical care group), two institutes (research institutes, education colleges) ), a modern, internationalized Chinese medicine group of several directly affiliated companies.

Tongrentang, while realizing the steady development of the economy, fully exerted the role of cultural carrier, especially the protection and inheritance of non-legacy culture has been widely recognized by all walks of life at home and abroad. Tongrentang has 10 non-legacy projects (including 3 at the national level). Under the strong support, help and guidance of governments at all levels, Tong Ren Tang actively contributes to the dissemination and promotion of Chinese medicine culture.

https://www.tongrentang.com/article/70.html

2021 Interim Report

19/8/2021

For the full release, see:

https://staticpacific.blob.core.windows.net/press-releases-attachments/1330379/HKEX-EPS_20210819_9900146_0.PDF

China National Pharmaceutical Group Co., Ltd. (Sinopharm)

About Us.

China National Pharmaceutical Group Co., Ltd. (Sinopharm) is a large healthcare group directly under the State-owned Assets Supervision and Administration Commission (SASAC) of the State Council, with 128,000 employees and a full chain in the industry covering R&D, manufacturing, logistics and distribution, retail chains, healthcare, engineering services, exhibitions and conferences, international business and financial services.

Sinopharm owns over 1,100 subsidiaries and 6 listed companies which are Sinopharm Group Co., Ltd. (Sinopharm Holding), China National Medicines Corporation Ltd., China National Accord Medicines Corporation Ltd., Beijing Tiantan Biological Products Co., Ltd., Shanghai Shyndec Pharmaceutical Co., Ltd., and China Traditional Chinese Medicine Holdings Co., Ltd.

The past years witnessed Sinopharm's steady and sound development. From 2009to 2018, the CAGR of revenue and total assets reached 24.24% and 30.54% respectively. Sinopharm ranked 169th in Fortune Global 500 and the revenue of 2018 amounted to nearly 400 billion yuan..

Sinopharm has built a nationwide logistic and distributing network for drugs and medical devices and equipment, including 5logistic hubs, more than 40 provincial-level centers and over 240 municipal-level logistic sites. By establishing the smart medical service system, Sinopharmdelivers quality servicesto more than 230,000 corporate clients.

Sinopharm has an applied pharmaceutical research institute and an engineering design institute, both taking a leading position in China. Two Academicians of Chinese Academy of Engineering, 11 national R&D institutes, 44 provincial-level technology centers and over 5,000 scientists have made remarkable achievements.Sinopharm also chaired in setting over 530 national technical criteria, among which the EV71 vaccine, a first category new drug of China with Sinopharm holding complete independent intellectual property right, reduces the morbidity of hand-foot-and mouth disease among Chinese children. The R&D and launch of sIPV ensures the progress of the national immunization program for polio.

Sinopharm has built up manufacturing and medicinal materials sites for biological drugs, narcotic and psychotropic drugs, anti-infectious drugs, oncology drugs, cardio-vascular drugs and respiratory drugs. Some of the production lines have been approved by the US FDA and EU authorities, and prequalified by WHO.

As world's 6th largest vaccine manufacturer, Sinopharm is able to produce all the vaccines in the National Vaccination Program and is the supplier of over 80% vaccines used in the Expanded Program on Immunization in China.

Sinopharm leads in TCM sector by establishing an integrated TCM industry chain that covers planting, R&D, pieces for decoction, formulated instant granules, and preparations. It is able to produce over 900 medicines,owns 15 China Time-honored Brands and 4 National Intangible Cultural Heritage medicines.

Sinopharmhas fostered 30 highly recognized events represented by CMEF (China International Medical Equipment Fair), serving the entire chain and many subdivisions concerning healthcare. These exhibitions and conferences have become a platform for exchange and cooperation that advances the whole industry.

Sinopharm explored a new model of drugstores with extensive healthcare services. There are over 5,100 chain drugstores under the brands of Guoda, Jinxiang, Dadesheng and Tianyitang, providing convenientaccess for customers. Sinopharm forms a healthcare network consisting of regional healthcare groups in provinces of Henan, Hubei, Liaoning, and Heilongjiang. Sinopharm provides easier access to healthcare services for the people in dozens of our medical institutions with more than 10,000 beds in total.

Sinopharm broadens its international cooperation by founding 26 joint ventures with world-renowned pharmaceutical companies andtrading with more than 120 countries and regions, including60 Belt and Road countries.

The JE vaccine of which Sinopharm owns complete independent intellectual property right has been listed into the procurement catalog by the UN organizations to benefit the whole world.Sinopharm'sproduction sites in Vietnam and Malaysia, along withthe China-aided hospitals and mobile clinicsconstructed by Sinopharm in Myanmar and Cambodia,not only provide jobs for the local people, but also make greatcontributions to their well-beings.

As healthcare-centered financial services develop, an industry-and-finance model with Sinopharm features takes shape.

Guided by the core value of "all for health, health for all", Sinopharm shoulders the social responsibility of national medical and pharmaceutical reserve on a long-term basis with pride. In times of epidemics and disasters, it provides medicines, bio-products, traditional Chinese medicines, and medical devices promptly to the stricken areas not only at home, but also abroad as in Ecuador earthquake relief and in Myanmar influenza A/H1N1 prevention and control, contributing to ensure a sound public health condition for the people.

Sinopharm acts as the president enterprise in many influential associations such as China Pharmaceutical Industry Association, China National Narcotic Drugs Association, China Association of Pharmaceutical Commerce, etc., and plays its role in preventing diseases, safeguarding people's health, and advancing the whole industry.

http://www.sinopharm.com/en/1398.html

C & O Pharmaceutical Technology Holdings

CORPORATE PROFILE.

C & O Pharmaceutical Technology (Holdings) Limited ("C&O" or "We") was incorporated in 2003 and history of its foundation can trace back to 1997. C&O has been achieving fast development in the rapid growth of China pharmaceutical market throughout these years. In 2011, we joined as the member with shareholding of 71% and 29% held under Shionogi & Co., Ltd. ("Shionogi") and Sumitomo Corporation ("Sumitomo") (collectively referred to as "the Headquarter"), respectively. In the process of the "Headquarter Globalization", we are playing an important role in China among the huge market activities.

C&O is one of the few pharmaceutical enterprises in China integrating functions of the research and development, manufacture, and marketing and distribution, which aims to achieve as the "New Drug Market Enterprise".

Technology Research and Development.

C&O owns two research and development centers now locating at Nanjing Economic Technology Development Zone and National Shanghai Biomedical Technology Industry Base, which are operated under its subsidiary, Nanjing Changao Pharmaceutical Technology Co., Limited ("Nanjing R&D") and Shanghai Sun-sail Pharmaceutical Science & Technology Co., Limited ("Shanghai Sun-sail"), respectively.

Nanjing R&D was established in 1999, which is the key "High and New Technology Enterprise" recognized under the "National Torch Program" in China, is mainly engaged in drug research and development both in the preclinical and clinical stage.

Shanghai Sun-sail was established in 2004 with strong capabilities and strengths in the synthesis and screening of new compounds, which is mainly engaged in the research and development of innovation drug covering areas in anti-drug-resistant bacteria, anti-drug-resistant tuberculosis, anti-diabetes and anti-insomnia.

C&O cares a lot works on the research and development of innovation and the protection of intellectual property. We have developed the mid to long term strategic planning for the development of intellectual property and apply the same to enhance the core competitiveness of enterprise in order for speeding up our development. At present, some innovation drugs with independently developed intellectual property had entered the clinical stage and the technical knowhow was successfully transferred. On the other hand, a number of innovative compounds have become ready in application for the clinical stage.

Industrial Production.

C&O owns its factory now locating at Jiangbei New Area Intelligent Manufacturing Industrial Park, Nanjing, Jiangsu Province ("the Factory"), which is operated under its subsidiary, Nanjing Chang Ao Pharmaceutical Co., Limited ("Nanjing Chang Ao"). Nanjing Chang Ao has been specializing in the manufacture of a wide range of drug formulations including the freeze-dried powder injection, solid preparations and externally used medicine with the production approval for 81 products, mainly including Aobo Ping® (Rabeprazole Sodium for Injection), Firest® (Pantoprazole Sodium for Injection), Fush*tan® (Pantoprazole Sodium Enteric-coated Capsules), Ophen® (Clarithromycin Dispersible Tablets) and Antaen® (Diclofenac Sodium Sustained Release Capsules/Diclofenac Sodium Gel), etc. It is renowned in the society and also recognized as the "High and New Technology Enterprise" by the Jiangsu Provincial Government.

In order to maintain best quality of drug, C&O had decided in 2012 to construct the Factory equipping with fully upgraded facilities and those constructions were then completed in 2016. The Factory mainly comprises of the Freeze-dried Powder Workshop, Ordinary Solid Workshop and External Drug Workshop, as well as the supporting facilities, such as storage, quality inspection and office premises, etc. Construction for the Factory was awarded the thorough national GMP certification following its completion in 2016 and the facilities are then put into use and production. The new facilities provide annual production capacity with 20 million of freeze-dried powder injection, 360 million of tablets, 300 million of capsules and 7.5 million of ointment and gel preparations.

The Factory currently produce various types of drugs covering antibiotics, cardiovascular and cerebrovascular drugs, and digestive system drugs, etc., mainly in the formulation of freeze-dried powder injection, tablets, capsules, and ointment and gel preparations. Those productions are conducted under sound system of production quality management.

While we utilize capacity of the GMP certified production facilities, we always keep products quality first and stable products supply. Meanwhile, Nanjing Chang Ao owns a large number of patented and "High and New Technology" products which have won many awards from the Jiangsu Provincial Government.

Promotion and Distribution.

Shenzhen Liancheng Medicine Company Limited ("Shenzhen Liancheng") is the C&O distribution center, which holds two subsidiaries, Nanjing Xinaokang Pharmaceutical Limited ("Nanjing Xinaokang") and Sichuan Changao Medicine Company Limited ("Sichuan Changao").

Shenzhen Liancheng and its subsidiaries have passed the new national GSP certification and the achievement represents that they have attained an upper level in respect of the drug quality risk control, cold chain management, computing software management system and people management.

The head office of Shenzhen Liancheng locates at Shenzhen Special Economic Zones, Guangdong Province. It is engaged in the distribution of prescription drug and OTC drug, mainly including the own branded product, Aobo Ping® (Rabeprazole Sodium for Injection) and the high quality imported product, Amoxycillin (Amoxicillin Capsules). As a large commercial distribution enterprise in the pharmaceutical industry, Shenzhen Liancheng place its focus on the business channels and distribution networks covering distributors, hospitals, clinics and pharmacies.

Having been experienced and contributed from the process of sales in the past 20 years, C&O has successfully built up the well known brand of antibiotic, "Amoxycillin", which is our exclusive distribution of imported product. In the 7 consecutive years from 2011 to 2017, it was on the list of "Health China - China Medicine Brand List". In additions, we launched the first "Rabeprazole Sodium for Injection - Aobo Ping®", in China in April 2014, which is our independently developed product.

On the launch of Aobo Ping®, it is the "Key Breakthrough" in field of the domestic digestive system drug over China and the market share of Aobo Ping® is now growing up.

C&O Pharmaceutical Technology (Holdings) Limited ("C&O" or "We") was incorporated in 2003 and history of its foundation can trace back to 1997. C&O has been achieving fast development in the rapid growth of China pharmaceutical market throughout these years. In 2011, we joined as the member with shareholding of 71% and 29% held under Shionogi & Co., Ltd. ("Shionogi") and Sumitomo Corporation ("Sumitomo") (collectively referred to as "the Headquarter"), respectively. In the process of the "Headquarter Globalization", we are playing an important role in China among the huge market activities.

http://english.changao.com/profile.html

http://english.changao.com/

Harbin Pharmaceutical Group Co., Ltd. (SHA: 600664)

Harbin Pharmaceutical Group Co., Ltd. (HPGC) is a state-controlled Sino-foreign equity joint venture. It is composed of domestically famous pharmaceutical companies like HPGC General Factory, HPGC Sanjing, HPGC Sixth Factory, HPGC Chinese Medicine, HPGC Bioengineering and HPGC Vaccine, and commercial circulation companies like HPGC Medicine, HPGC Sales and HPGC Marketing. HPGC has two listed companies, HPGC Holding and HPGC Sanjing. HPGC owns 45.06% equity stake in HPGC Holding, and HPGC Holding owns 74.82% equity stake in HPGC Sanjing. HPGC has more than 20,000 employees, and total assets of 18.5 billion RMB.

HPGC is integrated with pharmaceutical manufacture, trade and R&D. We have seven main business segments, which are antibiotics, small-molecular drug preparations, OTC and healthcare products, modern Chinese medicines, biopharmaceuticals, animal vaccines and medicine circulations. We produce more than 20 dosage forms and over 1000 drugs. The annual production capacity is 15 thousand tons of API and intermediates, 2 billion vials of small-molecule drug for injection, 100 million vials of Chinese medicine for injection, 180 million vials of solution injections, 11 billion tablets, 14 billion capsules, 2.2 billion vials of oral solutions and 30 billion doses of animal vaccines.

HPGC products are sold throughout China and more than fifty other countries. The market shares of cephalosporin APIs and preparations, healthcare product series of calcium supplements, and Chinese medicines for injection consistently rank first in the country. Part of our products has reached European, Asian, African, and Middle and North American markets. The annual foreign exchange earning is more than 100 million dollars. More than 100 products exceed revenue of 10 million RMB, over 30 of which exceed 100 million RMB.

HPGC has 5 Chinese Famous Trademarks, which are Hayao, Sanjing, Gaizhonggai, Hutong and Shiyitang. Hayao is one of the most valuable pharmaceutical brands in China and its brand value is evaluated to be worth 18.4 billion RMB. The operating profit and the main business revenue of HPGC have been in the front seats among Chinese Top 100 Pharmaceutical Companies for seven consecutive years since 2005.

In addition to establishing the strong brands, HPGC has put the rich resources accumulated by the aid of the famous brands into technology innovation. HPGC has been setting up the new R&D location - HPGC Pharmaceutical Academy since 2011. The R&D institute has full range of collaborations with domestic and international experts from prestigious universities and research institutes. Six research centers are established, which are research centers of small-molecule drugs, bioengineering drugs, drug preparations, modern Chinese medicines, OTC and healthcare products and animal vaccines. We have several innovative R&D platforms in the institute, such as technology platform of extended, controlled and immediate release, technology platform of fat emulsions, liposomes and lipid microspheres, and technology platform of biopharmaceutical PEGylation. With those platforms, we focus to develop our strength core technologies and products. We currently have over 140 new products. The penicillin and cephalosporin C fermentation technologies are in the world-advanced level. The constantly improved independent R&D system and the growing research team, along with the strong brands constitute the company's pair of wings.HPGC has received honors and awards including "Winner of Chinese Top 100 Pharmaceutical Companies","China's Most Respected Enterprise", "Champion of the Global Top 100 Chinese Companies", "China's Innovative Company with the Most Growth Potential", "Harbin Top 50 Taxpayers of Industry Companies", "the Top 10 Most Influential Pharmaceutical Enterprise Award", and "Key High-Tech Enterprise of National Torch Plan". They have brought wide attention and praise of the society to HPGC.

For year 2012, the gross industrial output of HPGC is 10.2 billion RMB, with revenue of 18 .0 billion RMB and profit of 885 million RMB.

Standing on the new start point that bears hope and vitality, HPGC will take practical actions to achieve leapfrog development under the new strategy of "Take a second pioneering journey through transformation and upgrade". We endeavor to join the Global 500 and become a world-class company with international competitiveness.

http://en.hayao.com/about/about1.html

North China Pharmaceutical Co., Ltd. (SHA: 600812)

North China Pharmaceutical Company Ltd. manufactures and markets pharmaceuticals. The Company produces antibiotic medicines, preparations, vitamins, immunomodulators, and other pharmaceutical products. North China Pharmaceutical markets its products worldwide.

https://www.bloomberg.com/quote/600812:CH

http://www.ncpc.cn/##

Jiangsu Hengrui Medicine Co., Ltd. (SHA: 600276)

Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a leading global pharmaceutical company headquartered in China with a focus on research, development, manufacturing, and commercialization of innovative and high-quality healthcare products. Innovation is the core development strategy. we have focused our R&D efforts in antineoplastic drugs, surgery medications, and medicines that treat autoimmune diseases, metabolic diseases and cardiovascular diseases. Hengrui Pharma has been on the Pharma Exec's annual listing of the top 50 global pharmaceutical companies for the fifth consecutive year. Hengrui Pharma ranked 24th among the top 1,000 global pharma companies announced by the Torreya in 2021. Hengrui Pharma ranked 13th in the "Top 25 global pharma companies by pipeline size " selected by Informa Pharma Intelligence in 2023.

Innovation is the core of Hengrui's development strategy. Hengrui spent more than 850 million USD (6.35 billion RMB) in R&D in 2022, which is 29.83% of the 2022 revenue. We have built a large-scale, professional, and comprehensive innovative drug research staff of more than 5,000 people. Fourteen R&D centers were built around the world and several subsidiaries were established in the US, EU, Australia, and Japan. Hengrui Pharma has 13 in-house developed innovative products and 2 in-licensed innovative products marketed in China , more than 80 innovative candidates in the R&D stage and nearly 20 innovative products under clinical development around the world. As of June 2023, 2208 patent applications have been submitted, with 572 patents granted in China and 656 patents granted worldwide, such as the US, EU, and Japan.

Internationalization is also an important development strategy of Hengrui. By the end of 2022, Hengrui's products have entered more than 40 countries, and will continue to accelerate global market development, focusing on emerging markets. Hengrui has established manufacturing facilities all over the country . All of its exported products meet or exceed the standards specified in the European Union and US Pharmacopoeia. We have exported injections on a large scale to the US, EU, and Japan markets. Through our international partners, Hengrui has obtained more than 20 registration approvals including injections, oral preparations and inhalation anesthetics in the EU, US and Japan to benefit more patients around the world.

Hengrui will continue its engagement in the innovation and development of treatments for various diseases spanning oncology, metabolic diseases, autoimmune diseases, cardiovascular diseases, and other therapeutic areas to benefit patients globally.

https://www.hengrui.com/en/about.html

Jiangsu Hengrui Pharmaceutical Co., Ltd. - 2024 First Quarter Report

18/4/2024

For the Chinese language, see:

https://php.cnstock.com/texts/2024/20240417/65A3291AE0D3A9CB83E9C6BBEA5B95B2.pdf

Livzon Pharmaceutical Group (SHE: 000513)

Livzon Pharmaceutical Group Co., Ltd. was founded in January 1985. It is a comprehensive pharmaceutical group company integrating R&D, production and sales of pharmaceutical products. It is an A+H-share listed company. In 2023, the company's operating income was 12.43 billion yuan, net profit was 1.954 billion yuan, and R&D investment was 1.235 billion yuan, accounting for 9.94% of operating income.

The company regards R&D innovation as the cornerstone of sustainable development, continues to pay attention to new molecules and cutting-edge technologies in the field of global new drug research and development, and deploys innovative drugs and high-barrier complex preparations based on clinical value and differentiation, focusing on the digestive tract, assisted reproduction, mental health, and tumor immunity. In other fields, a complete product cluster and a differentiated product pipeline covering the entire R&D cycle have been formed.

In the field of chemical drugs: innovative drugs + high-barrier complex preparations drive development. The company has outstanding blockbuster products in the field of digestive tract. Following Livzon Dela, it has independently developed a series of ilaprazole products, the only domestically produced innovative drug among PPIs. It has unique advantages such as small dosage, fast onset of effect, and long maintenance time, and has been clinically used for more than 10 years. In 2016, it has a wide market coverage and a good reputation. P-CAB, another blockbuster innovative drug for the digestive tract, is about to be submitted for clinical application. At the same time, as a leading enterprise in domestic microsphere preparations, Livzon has mastered the production process of microsphere preparations with high technical barriers, and established a national and local joint engineering research center for long-lasting microsphere technology. It has developed leuprolide acetate for injection. Microspheres are one of the first products to achieve localization of microspheres, breaking the long-term foreign monopoly. Triptorelin acetate microspheres for injection were approved for marketing in May 2023, and aripiprazole microspheres for injection have been successfully reported for production. There are also a number of microspheres, implants, transdermal patches, and orally dissolving films. High-end complex preparation products such as oral sustained-release and controlled-release products are distributed in various stages of research and development.

In the field of biopharmaceuticals: Focusing on the fields of autoimmune diseases, tumors and assisted reproduction, focusing on new molecules, new targets and differentiated molecular design, a typical demonstration base for the industrialization of antibody drugs in Guangdong Province has been built. It is a technology platform that integrates strain screening, large-scale cell culture, purification, preparation, analysis and testing, and quality control. Biosimilar injection recombinant human chorionic gonadotropin and tocilizumab injection were approved for marketing in China in April 2021 and January 2023 respectively, and the innovative drug recombinant new coronavirus fusion protein vaccine (CHO cell) was launched in 2022 It was approved for national emergency use in June 2016. Recombinant human follicle-stimulating hormone injection and recombinant anti-human IL-17A/F humanized monoclonal antibody injection are both undergoing Phase III clinical trials, and multiple R&D projects are in different stages of clinical research.

In the field of APIs: focusing on high-end specialty APIs, the products have significant competitive advantages in terms of scale, quality, etc., and many APIs and intermediate products have leading global market shares; actively promote overseas certification work and international market development layout, and accelerate internationalization. In the process of globalization, it has increasingly become a long-term strategic partner of leading companies in the global pharmaceutical industry such as Pfizer and Teva.

See Also

cost of dimethyl isosorbide

Field of Traditional Chinese Medicine : At present, the National Traditional Chinese Medicine Modernization Engineering Technology Research Center and 4 provincial-level R&D centers have been established, and large-scale traditional Chinese medicine GAP planting bases have been built in Hunyuan, Shanxi, Longxi, Gansu and other places, covering R&D, planting, production, and sales. Carry out the layout of the entire industrial chain of traditional Chinese medicine. There are currently 21 exclusive varieties, among which the flagship products Shenqi Fuzheng Injection and Antiviral Granules have experienced strong growth. There are also exclusive products such as Jingfu Zhiyang, Bazheng Capsules, and Children's Lung Heat, covering various areas of traditional Chinese medicine treatment.

In the field of in vitro diagnostic reagents: Focusing on strategic disease areas and the layout of departments, we rely on mature product lines to develop detection reagents for multiple diseases in parallel. We currently have multiple liquid phase chips, chemiluminescence, molecular diagnostics, raw materials and basic research, It has multiple technology platforms such as automation equipment, and its market share is in a leading position in the country in the fields of respiratory infectious diseases, major infectious diseases, drug concentration monitoring and other fields.

In the future, Livzon will continue to adhere to its mission of "putting patients' life quality first" and its vision of "being a leader in the pharmaceutical industry", focusing on the field of life and health, continuing to be guided by patients' clinical needs, and accelerating improvement through digital and intelligent technology models. R&D efficiency, further strengthening its leading advantages in innovative drugs and high-barrier complex preparation platforms, and comprehensively improving sustainable development capabilities. At the same time, we will actively respond to national policy calls, continue to shoulder the responsibilities of pharmaceutical companies, and make more contributions to a healthy China.

https://www.livzon.com.cn/intro/2.html

2024 First Quarter Report

23/4/2024

For the Chinese language, see:

https://www.livzon.com.cn/public/html/pdfjs/viewer/viewernew.html?file=https://v4.cecdn.yun300.cn/site_1809140982/C_2024_first_quarterly_report_20240423_ESS1713867546162.pdf

North China Pharmaceutical Co., Ltd. (SHA: 600812)

https://www.bloomberg.com/quote/600812:CH

http://www.ncpc.cn/##

Northeast Pharmaceutical Group Co., Ltd (SHE: 000597)

For the Chinese language, see:

https://www.nepharm.com.cn/article/index/cid/2.html

Northeast Pharmaceutical: First Quarter Report of 2024

26/4/2024

For the Chinese language, see:

http://www.cninfo.com.cn/new/disclosure/detail?plate=szse&orgId=gssz0000597&stockCode=000597&announcementId=1219830877&announcementTime=2024-04-26

Shanghai Pharmaceuticals Holding Co., Ltd. (SHA: 601607, HK: 2607)

Shanghai Pharmaceuticals Group Co., Ltd. (hereinafter referred to as "Shanghai Pharmaceuticals" or the "Company") is a large pharmaceutical industry group listed in Shanghai and Hong Kong (HKEx stock code: 02607; Shanghai Stock Exchange stock code: 601607). The company's registered capital is 3.703 billion yuan. Its main business covers the pharmaceutical industry and commerce. Its operating income in 2023 is 260.3 billion yuan. It ranks among the Fortune Global 500 and the top 50 global pharmaceutical companies. Its comprehensive strength ranks among the top three Chinese pharmaceutical companies. It was selected SSE 180 Index, CSI 300 Index constituent stocks, Morgan Stanley China Index (MSCI).

Shanghai Pharmaceuticals advocates the core corporate values of "innovation, integrity, cooperation, tolerance and responsibility", is committed to perseverance, improves the quality of people's healthy life, and strives to become a respected and leading brand drug manufacturer with industry reputation and health field. service provider.

https://www.sphchina.com/about_us/sph_overview.html

Shanghai Pharmaceutical Group Co., Ltd. - 2024 First Quarter Report

29/4/2024

For the Chinese language, see:

https://www.sphchina.com/attached/files/20240426001.pdf

Shandong Xinhua Pharmaceutical Co., Ltd. (HK: 719)

Shandong Xinhua Pharma. I&E Co.,Ltd. is a wholly owned subsidiary of Shandong Xinhua Pharmaceutical Co.,Ltd (a Public listed company,HKEX 0719,SZSE 000756).We specialize in the import and export chemical intermediates manufactured by our parent company and local audited partners,including companies of our parent group, Hualu holding .

We are executive member of the Shandong Pharm.Industry Association.

We have accumulated ample experience in dangerous or hazardous chemical management since we started exporting businesses in 1992.

We utilize advanced QC labs and QA systems operated by our parent company. These systems are subject to at least two rigorous official audits every year from the FDA,PMDA,MHRA,TGA,NMPA, as well as over 50 annual quality audits from leading pharmaceutical firms.Thus, we are competent to assure resource quality.

Our Mission:

For the perfect source.

Our Products:

APIs in FDA approved facility, PVC stabilizers catalyst, pigment intermediates, water chemicals, paint chemicals, pharmaceutical intermediates, agrochemicals, amino acids for peptide synthesis, solvent for biotechnology, food ingredients.

https://www.shandongxinhuapharma.com/about-us

Unaudited results for the first quarter of 2024

25/4/2024

For the Chinese language, see:

http://xhzy.com/uploads/soft/20240425/1714051035.pdf

Shenzhen 999 Enterprise Group Co., Ltd.

Founded in December 1991, Sanjiu Enterprise Group, a state-owned enterprise directly supervised by the Stat Department, is one of the biggest herbal product manufacturers in China. Throughout 14 years' painstaking efforts, Sanjiu has developed into a national-famed integrated enterprise group, which presently is the controlling shareholder of companies (SANJIU MEDICAL & PHARMACEUTIAL Co., Ltd. ) and other 20 GMP standard pharmaceutical companies, many of which have been granted the TGA certificate of the Commonwealth of Nations. Featured by the core business domain of health industry and with the capability of manufacturing over 1, 000 sorts of herbal and chemical medicines in wide varieties of preparations, such as capsule, granule, oral liquid, injections powders, etc.Sanjiu made a turnover of RMB 8.6 billion yuan in 2004. And the 999 trademark has become a world famous health product brand, whose intangible assets has reached RMB 8.3 billion yuan.

Shenzhen 999 Chinese Medicine Investment & Development Co., Ltd., as a wholly owned key subsidiary company of Sanjiu Enterprise Group, is fully authorized to be in charge of Sanjiu's international health product market. It is responsible for the investment and management of the overseas subsidiary companies and (Traditional Chinese Medicine) clinics and supplies technological support for all the overseas agencies of the 999 health product. So far, we have set up our subsidiary companies in Hong Kong, Malaysia and Canada, and many clinics, with the products spread over the market of North America, Europe, Japan, Middle East and Southeast Asia. We are featured by Chinese Patent medicines, Health Food, Single Herbal Extracts, botanical extracts, injections and decocting machine. Many famous products such as 999 Weitai, 999 Ganmaoling, ZhuangGu Guan Jie Wan pills, Zheng Tan Wan pills, 999 Pi Yan Ping Ointment have been registered in many different counties. Besides, the chemical, biological medicines and raw materials presented by Sanjiu also provide the consumers more choices for medical treatment. Furthermore, based on our advantages of technologies and manufacturing scales, we are now supplying first-class OEM services to meet the demand of different markets from all over the world.

http://999sanjiu.en.made-in-china.com/

Sinopharm (China National Pharmaceuticals Group Co Ltd) (HKSE: 01099)

About Us.

As healthcare-centered financial services develop, an industry-and-finance model with Sinopharm features takes shape.

http://www.sinopharm.com/en/1398.html

Sinopharm Group Co., Ltd (HK: 1099)

The company is a core enterprise of China National Pharmaceutical Group Corporation. It was established in January 2003 and listed on the Hong Kong Stock Exchange in September 2009 (stock code: 01099.HK). It is China's largest pharmaceutical, medical device and healthcare company. Product wholesalers and retailers, and leading supply chain service providers.

The Group is mainly engaged in the distribution business of pharmaceuticals and medical devices. Relying on a nationwide distribution and distribution network, the Group serves domestic and foreign manufacturers and suppliers of pharmaceuticals, medical devices, consumables and other healthcare products, as well as downstream hospitals, other distributors, Provide comprehensive distribution, delivery and other value-added services to customers such as retail pharmacies and primary medical institutions.

At the same time, the Group manages retail chain drugstore networks in major cities in China through direct operation and franchise operations, and sells medicines and general health products to end consumers. It now occupies a leading position in China's pharmaceutical retail industry.

In addition, the Group is also engaged in the manufacturing and sales of pharmaceuticals, chemical preparations and laboratory supplies, and is actively innovating in pharmaceutical, medical and other health-related industries to explore the collaborative development of diversified businesses.

Relying on the established scale advantages, customer resources, network platform and brand status, the Group will make full use of the steady growth of the market environment of China's pharmaceutical and healthcare industry, seize the opportunities of the medical system reform, further consolidate and enhance its market leading position, and continue to forge ahead. , striving to become an efficient pharmaceutical supply chain organizer and industry comprehensive service solution provider.

http://ir.sinopharmgroup.com.cn/c/about.php

Announcements and Notices - Announcement of Quarterly Financial Information for the Three Months Ended March 31,

29/4/2024

For the Chinese language, see:

https://media-sinopharm.todayir.com/20240429080801846611185100_tc.pdf

Sinovac Biotech (NASDAQ: SVA)

Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.

SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, and mumps.

The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and was commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.

SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.

SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.

http://www.sinovac.com/en-us/about

SINOVAC Reports Unaudited Second Half of 2023 Financial Results and Files 2023 Annual Report on Form 20-F

30/4/2024

Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, has filed its 2023 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2023. The annual report can be accessed on the Company's investor relations website at http://www.sinovac.com/en-us/Investors. The Company also reported its unaudited financial results for the second half and audited financial for the full year ended December 31, 2023.

Second Half and Full Year 2023 Financial Summary

Sales for the six months ended December 31, 2023 were $307.9 million, compared to $280.5 million in the prior year period.

Sales in 2023 were $448.3 million, compared to $1.5 billion in the prior year.

The Company posted $119.9 million of net loss attributable to common shareholders, or a loss of $1.20 per basic and diluted share, in the six months ended December 31, 2023, compared to net loss attributable to common shareholders of $373.7 million, or a loss of $3.76 per basic and diluted share, in the prior year period.

The Company posted $105.9 million of net loss attributable to common shareholders, or a loss of $1.06 per basic and diluted share in 2023, compared to net income attributable to common shareholders of $107.9 million, or $1.08 per basic and $1.00 per diluted share, in the prior year period.

Mr. Weidong Yin, Chairman, President and CEO of SINOVAC, commented "In 2023, SINOVAC has gradually adjusted from the state of mass supply of COVID-19 vaccine against pandemic back to normal operational status. I am pleased to see that the top line of our regular products still maintained growth in the year of 2023. After experiencing three years of the COVID-19 pandemic, the world is still facing the threat of various infectious diseases in 2023. As a leading biopharmaceutical products provider in China, SINOVAC continues to invest additional resources in R&D and production of vaccines, and keeps exploring additional opportunities in a broader biopharmaceutical industry. It is great to see every progress of our pipeline products, such as the recent approval of 5-dose sIPV from National Medical Products Administration (NMPA) and the approval of clinical trial for reassortant hexavalent rotavirus vaccine. Meanwhile, we are maintaining a strong international presence by providing high quality vaccines and localized production outside of China."

Business Updates

Hepatitis A Vaccine - Healive®, the first and only WHO prequalified inactivated hepatitis A vaccine from China, is currently supplied both domestically and internationally. Healive®'s performance in public tender market in China was further improved in 2023.

Influenza Vaccine - A new and state-of-the-art influenza vaccine production line started operations in Beijing. The plant, which complies with Chinese Good Manufacturing Practice guidelines and utilizes green production processes, enables automated production at scale that expands SINOVAC's capacity to meet the growing global demand for high-quality influenza vaccines. SINOVAC's influenza vaccines expand international market accessibility in 2023 by obtaining more overseas market approvals, such as in Pakistan and Chile. A study conducted recently in the Philippines and Chile demonstrated that the immunogenicity induced by SINOVAC's quadrivalent influenza vaccine was non-inferior and the geometric mean titers were even higher in individuals aged 3 years and older, when compared with the control vaccine which was widely used.

Varicella Vaccine - SINOVAC's live attenuated varicella vaccine, the first WHO prequalified Chinese varicella vaccine, was successfully supplied to Türkiye this year. The varicella vaccine was also registered in Lebanon and Kenya in 2023.

Hand Foot and Mouth Disease Vaccine - SINOVAC's Enterovirus 71 (EV71) vaccine, Inlive®, has already safeguarded millions of children in China. In 2023, SINOVAC has initiated phase I clinical trials of its bivalent enterovirus inactivated vaccine, which aims to protect against hand, foot and mouth disease (HFMD) caused by enterovirus 71 (EV71) and coxsackievirus 16 (CA16).

Strategic Developments - We achieved several milestones in the strategic development in 2023. In Türkiye, our first joint venture with a local partner has successfully completed construction of a vaccine production plant, and a GMP certificate was obtained from the Turkish Medicines and Medical Devices Agency. In Latin America, we participated in a tender issued by the government of Bogota, Colombia, for localizing human vaccine production, and we were successfully selected as the exclusive strategic partner with BogotáBio, a local vehicle for the localization project, which aims to build the first local human vaccine production facility with municipal partner in Colombia's capital of Bogota. SINOVAC's extensive expertise and experience in vaccine R&D and production, and its successful track record in establishing vaccine manufacturing facilities will play a pivotal role in the new venture. At the end of 2023, SINOVAC completed an investment in Synermore Biologics (Suzhou) Co., Ltd., a company which focuses on the development and production of monoclonal antibody drugs in the fields of infectious diseases, malignant tumors and autoimmune diseases. The investment marks a key step for SINOVAC entering into the novel antibody drugs field.

Unaudited Financial Results for the Second Half of 2023

Sales for the second half of 2023 were $307.9 million, compared to $280.5 million in the prior year period. The increase was mainly due to increased sales of our influenza vaccines.

Selling, general and administrative expenses in the second half of 2023 were $235.3 million, compared to $667.7 million in the prior year period. The decrease was mainly due to lower expenses incurred in the COVID-19 employee incentive plan which was established in 2022.

R&D expenses in the second half of 2023 were $193.4 million, compared to $257.7 million in the prior year period.

Net loss in the second half of 2023 was $228.3 million, compared to net loss of $702.3 million in the prior year period.

Net loss attributable to common shareholders was $119.9 million, or a loss of $1.20 per basic and diluted share, in the second half of 2023, compared to a net loss attributable to common shareholders of $373.7 million, or a loss of $3.76 per basic and diluted share, in the prior year period.

As the Company announced on February 22, 2019, the Company's board of directors determined that certain shareholders became acquiring persons, as defined in the Company's rights agreement ("Rights Agreement"), under which a trigger event occurred. As a result, the Company issued new common and preferred shares of SINOVAC. Without the effect of implementing the Rights Agreement and newly-issued common and preferred shares, basic and diluted loss per share for the second half of 2023 would be $1.63.

Non-GAAP adjusted EBITDA was a loss of $111.6 million in the second half of 2023, compared to a loss of $998.7 million in the prior year period. Non-GAAP net loss was $183.0 million in the second half of 2023, compared to a net loss of $805.8 million in the prior year period. Non-GAAP diluted loss per share in the second half of 2023 was $0.93 compared to a loss of $4.38 per share in the prior year period. Non-GAAP diluted loss per share in the second half of 2023, excluding the implementation of the Rights Agreement and the newly-issued common and preferred shares, would be $1.29. Reconciliations of non-GAAP measures to the nearest comparable GAAP measures are included at the end of this earnings announcement.

The Company's financial statements for the second half of 2023 are prepared and presented in accordance with U.S. GAAP. However, they have not been audited or reviewed by the Company's independent registered accounting firm.

Financial Results for the Twelve Months Ended December 31, 2023

Sales in 2023 were $448.3 million, a decrease from $1.5 billion in the prior year. The decrease was due to decreased sales of CoronaVac®.

Selling, general and administrative expenses in 2023 were $466.3 million, compared to $823.5 million in the prior year. The decrease was mainly due to lower expenses incurred in the COVID-19 employee incentive plan which was established in 2022.

R&D expenses in 2023 were $344.5 million, compared to $442.1 million in the prior year. The Company continued to invest in the advancement of pipeline vaccines in 2023.

Net loss in 2023 was $258.4 million, compared to a net income of $88.1 million in the prior year. Net income decreased primarily due to decreased sales.

Net loss attributable to common shareholders was $105.9 million, or a loss of $1.06 per basic and diluted share, compared to net income attributable to common shareholders of $107.9 million, or $1.08 per basic and $1.00 per diluted share, in the prior year.

Excluding the implementation of the Rights Agreement, as described above, and the newly-issued common and preferred shares, basic and diluted loss per share for 2023 would be $1.39.

Non-GAAP adjusted EBITDA was a loss of $458.3 million in 2023, compared to a loss of $309.5 million in the prior year. Non-GAAP net loss in 2023 was $303.9 million, compared to a net loss of $177.0 million in the prior year. Non-GAAP diluted loss per share in 2023 was $1.32, compared to a loss of $0.37 per share in the prior year. Non-GAAP diluted loss per share in 2023, excluding the implementation of the Rights Agreement and the newly-issued common and preferred shares, would be $1.84 per share. Reconciliations of non-GAAP measures to the nearest comparable GAAP measures are included at the end of this earnings announcement.

As of December 31, 2023, cash and cash equivalents and restricted cash totaled $1.3 billion, compared to $4.3 billion as of December 31, 2022. In 2023, net cash provided by operating activities was $104.0 million, net cash used in investing activities was $2.9 billion, and net cash used in financing activities was $76.1 million. As of December 31, 2023, the Company had $76.1 million in bank loans due within one year. The Company expects that its current cash position will be able to support its operations for at least the next 12 months.

Legal Proceedings

As previously disclosed by the Company, on March 13, 2018, 1Globe Capital LLC ("1Globe") filed a complaint against the Company in the Antigua Court. The trial of the matter took place from December 3 to 5, 2018. On December 19, 2018, the Antigua judge handed down his judgment (the "Antigua Judgment"), finding the Company fully in favor, dismissing 1Globe's claim and declaring the Rights Agreement was validly adopted as a matter of Antigua law. On January 29, 2019, 1Globe filed a Notice of Appeal against the Antigua Judgment. On March 4, 2019, 1Globe filed an application for urgent interim relief, seeking an injunction to prevent the Company from continuing to implement its Rights Agreement until the resolution of the appeal. This application was heard on April 4, 2019, at which the Court of Appeal issued an order restraining the Company from operating the Rights Agreement in any way that affects 1Globe's rights or shareholding or otherwise distributing the exchange shares (the "Exchange Shares") to the Company's shareholders who did not trigger the Rights Plan until after the determination of the appeal (the "Exchange Shares"). 1Globe's appeal against the Antigua Judgment was heard on September 18, 2019, and the appeal decision was announced by the Eastern Caribbean Supreme Court, Court of Appeal (the "Court of Appeal") on December 9, 2021, upholding the Antigua Judgment in each point. 1Globe applied for leave to appeal to the Judicial Committee of the Privy Council (the "Privy Council"), and the hearing of the application was held on February 24, 2022, in which the Court of Appeal granted 1Globe leave to appeal to the Privy Council on certain grounds, although not including the challenge to the validity of the Rights Agreement. On April 19, 2022, 1Globe renewed its application directly to the Privy Council for leave to appeal on its ground of appeal concerning the validity of the Rights Agreement. The final substantive hearing before the Privy Council is listed for July 10 to 11, 2024. The judgment will be reserved and delivered in writing at a later date. The appeal outcome is therefore pending.

As previously disclosed, on March 5, 2018, the Company filed a lawsuit in the Court of Chancery of the State of Delaware, seeking a determination on whether 1Globe, the Chiang Li Family, OrbiMed Advisors, LLC and certain other shareholders of the Company had triggered the Rights Agreement. On April 12, 2018, 1Globe filed an amended answer to the Company's complaint, counterclaims and a third-party complaint against the Company and Mr. Weidong Yin, alleging, among other allegations, that the Rights Agreement is not valid. On March 6, 2019, the Delaware Chancery Court entered a status quo order, providing that the Company not distribute any of the Exchange Shares to the Company's shareholders who did not trigger the Rights Plan until the final disposition of the pending Delaware litigation or further order of the Court. On April 8, 2019, the Delaware Chancery Court stated that the Delaware litigation was pending the final outcome of 1Globe's appeal of the Antigua Judgment.

Separately, Heng Ren Investments LP ("Heng Ren") filed suits against SINOVAC and Weidong Yin on May 31, 2019 in Massachusetts state court for the alleged breach of fiduciary duties and wrongful equity dilution. SINOVAC moved the matter from the state court to the United States District Court for the District of Massachusetts. Heng Ren alleged that Mr. Yin breached fiduciary duties owed to minority shareholders, that SINOVAC aided and abetted breaches of fiduciary duties and that both SINOVAC and Mr. Yin engaged in wrongful equity dilution. Heng Ren requested damages, attorney fees, and prejudgment interest. In July 2021, SINOVAC moved to dismiss Heng Ren's amended complaint in the federal court in Massachusetts. On March 4, 2022, the court granted the motion as to the breach of fiduciary duty claims and denied the motion as to the wrongful equity dilution claim and denied reconsideration of its decision on the motion. SINOVAC has answered the complaint. Pursuant to the current schedule, the close of fact discovery is April 26, 2024, the deadline for initial summary judgment motions is August 23, 2024, and, should the case not be resolved through settlement or at summary judgment, trial is set to begin on December 9, 2024.

On September 6, 2023, MW Gestion, an institutional asset manager based in France, filed a class action complaint on behalf of all SINOVAC shareholders against SINOVAC; Weidong Yin; and other managers and directors of SINOVAC, including Nan Wang, Simon Anderson, Yuk Lam Lo, Kenneth Lee, Meng Mei, and Shan Fu (the "Individual Defendants" and collectively with SINOVAC the "SINOVAC Defendants"); and Wilmington Trust National Association. MW Gestion alleges breach of contract, breach of fiduciary duty, and wrongful dilution claims against the SINOVAC Defendants, as well as aiding and abetting breach of contract and breach of fiduciary duty against the Individual Defendants. MW Gestion's claims stem from a private investment in public equity transaction on July 2, 2018, and SINOVAC's implementation of its Rights Agreement on February 22, 2019. SINOVAC and certain other defendants filed a motion to dismiss all claims on November 20, 2023, and the motion was fully briefed as of February 27, 2024.

Status of Exchange Shares and Trading in the Company's Shares

As a result of the pending legal proceedings described above, the Exchange Shares are expected to remain in a trust for the benefit of the Company's shareholders who did not trigger the Rights Plan until, at least, the conclusion of the appeal against the Antigua Judgment and the final disposition of the Delaware litigation or further order of the Delaware Chancery Court. The Exchange Shares remain issued and outstanding. The Nasdaq Stock Market LLC implemented a halt on trading of the Company's common shares at the time the Exchange Shares were issued to the trust. The Company is currently unable to estimate when trading will resume, or if Nasdaq will take any additional action in regard to trading of the Company's common shares.

http://www.sinovac.com/en-us/news/id-3317

WuXiAppTec Co., Ltd. (SHA: 603259, HK: 2359)

Established in December 2000, WuXiAppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXiAppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient solutions. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXiAppTec's open-access platform is enabling more than 3,600 collaborators from over 30 countries to improve the health of those in need - and to fulfill our dream that "every drug can be made and every disease can be treated."

https://www.wuxiapptec.com/about/overview

WuXi AppTec Achieved First Quarter 2024 Target Despite External Challenges, Maintaining Stable Operations

2024/04/29

Revenue Reached RMB7,982 Million; Excluding COVID-19 Commercial Projects, Down 1.8%

Net Profit Attributable to the Owners of the Company Reached RMB1,942 Million; Diluted Earnings per Share (EPS) Reached RMB0.66

Adjusted Non-IFRS Net Profit Attributable to the Owners of the Company Reached RMB1,913 Million; Adjusted Non-IFRS Diluted EPS Reached RMB0.65[1]

Free Cash Flow Remained Positive and Reached RMB1,326 Million

(SHANGHAI, April 29, 2024) - WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and life sciences industry, today announced its financial results for the first quarter ending March 31, 2024 ("Reporting Period"):

Revenue reached RMB7,982 million; excluding COVID-19 commercial projects, revenue down 1.8%.

Adjusted non-IFRS gross profit reached RMB3,090 million. Adjusted non-IFRS gross profit margin was 38.7%.

Net profit attributable to the owners of the Company reached RMB1,942 million; diluted EPS reached RMB0.66. Adjusted non-IFRS net profit attributable to the owners of the Company reached RMB1,913 million; adjusted diluted non-IFRS EPS reached RMB0.65.

Free cash flow remained positive and reached RMB1,326 million.

In the first quarter of 2024, we added over 300 new customers, and in total we served more than 6,000 active customers over the past 12 months. Demand from customers across regions globally continued to grow.

During the Reporting Period, revenue from the top 20 global pharmaceutical companies reached RMB2.70 billion, which grew 4.2% year-over-year excluding COVID-19 commercial projects.

The sustained and steady business growth is attributed to our unique fully integrated Contract Research, Development and Manufacturing Organization (CRDMO) platform. WuXi Chemistry's D&M pipeline has maintained rapid growth, with a total of 337 new molecules added in the Reporting Period. As of March 31, 2024, our D&M pipeline reached 3,286 molecules, among which 11 commercial and phase III projects were added during the Reporting Period.

As an enabler of innovation and a trusted partner and contributor to the global pharmaceutical and life sciences industry, the Company is committed to environmental sustainability efforts. The Company was named to the S&P Global Sustainability Yearbook and recognized as an Industry and Regional "Top-Rated" company by Sustainalytics consecutively in 2023 and 2024. Our outstanding ESG performance has also been widely acknowledged by major global ESG rating agencies, including MSCI, CDP, EcoVadis and FTSE Russell.

The Company adheres to the unwavering commitment to customers' IP protection and the highest quality & compliance standards. In 2023, the Company has received a total of 748 quality audits and inspections conducted by global customers, regulatory authorities and independent third parties, and achieved 100% pass rate with no critical findings. The Company also received 83 information security audits conducted by global customers, with no critical findings. In addition, 24 of our main operating sites are ISO/IEC 27001 certified, including all the main operating sites in China.

Management Comment

Dr. Ge Li, Chairman and CEO of WuXi AppTec, said, "We achieved our targets for the first quarter of 2024. For the full year, the Company expects to deliver revenue of RMB 38.3-40.5 billion and free cash flow of RMB 4-5 billion, while adjusted non-IFRS NPM is expected to remain at a similar level as last year."

"Since its founding in 2000, WuXi AppTec has dedicated itself to serving as a highly efficient enabler to the industry, creating value for our customers and benefiting patients globally. Over the past two decades, the Company has remained fully committed to the highest quality and compliance standards, prioritizing our customers' needs, protecting their intellectual property (IP), and abiding by the laws and regulations in the countries in which we operate. Thanks to the trust and support from our customers globally, the Company continues to support the industry and enable our customers with continuously enhanced capabilities and capacity. With constantly emerging scientific innovations, including the rapid development of artificial intelligence (AI), the industry's demand for CRO, CDMO, CRDMO and CTDMO services will continue to grow - and this is the inevitable trend of the industry. Although the recently proposed U.S. legislation may create short-term uncertainty for the Company, our customers and the global pharmaceutical and life sciences industry, WuXi AppTec remains steadfast in 'doing the right thing and doing it right' and in supporting our customers' efforts to bring groundbreaking therapies to patients around the world."

Business Performance by Segments

WuXi Chemistry: Integrated CRDMO Business Model Drives Steady Growth, with Continued Expansion in New Modalities (WuXi TIDES)

Revenue from WuXi Chemistry reached RMB5.56 billion; excluding COVID-19 commercial projects, revenue down 0.6%. Adjusted non-IFRS gross profit margin was 43.3%.

Discovery chemistry services ("R") continued to generate downstream opportunities. In the past 12 months, we successfully synthesized and delivered more than 430,000 new compounds to customers, which grew 3% year-over-year. Through our "follow-the-customer" and "follow-the-molecule" strategies, we established trusted partnerships with our customers globally, supporting the sustainable growth of our CRDMO business.

Development and manufacturing (D&M) services delivered sustained growth.

D&M services revenue[2] reached RMB4.00 billion; excluding COVID-19 commercial projects, D&M services revenue grew 1.2% year-over-year.

In the Reporting Period, we added 337 new molecules to our D&M pipeline. As of March 31, 2024, our D&M pipeline reached 3,286 molecules, including 64 commercial projects, 74 in phase III, 345 in phase II and 2,803 in phase I and pre-clinical stages, among which 11 commercial and phase III projects were added during the Reporting Period.

l Specifically, TIDES business (mainly oligo and peptides) continued to expand.

In the Reporting Period, TIDES revenue grew strongly by 43.1% year-over-year to RMB0.78 billion. As of March, 31, 2024, backlog of TIDES grew significantly by 110% year-over-year.

In the Reporting Period, the number of TIDES D&M customers increased 30% year-over-year to 146, and the number of TIDES molecules increased 43% year-over-year to 276.

In January 2024, the total reactor volume of solid phase peptide synthesizers increased to 32,000L.

WuXi Testing: Drug Safety Evaluation Service & Site Management Organization (SMO) Maintain Leadership Position and Drive Steady Growth

Revenue from WuXi Testing reached RMB1.49 billion. Adjusted non-IFRS gross profit margin was 35.6%.

Revenue from lab testing services down 0.6% year-over-year to RMB1.05 billion. Among which, revenue from drug safety evaluation services grew 3.7% year-over-year. We maintained our industry-leading position in the Asia-Pacific region.

In the first quarter, the Chengdu facility received National Medical Products Administration (NMPA) GLP qualification; the Qidong facility received Organization for Economic Co-operation and Development (OECD) and NMPA GLP qualifications in March and April. An additional 22,000m2 of facilities were GLP-qualified in the first quarter.

Revenue from clinical CRO & SMO grew 11.0% year-over-year to RMB0.44 billion. SMO revenue grew 26.4% year-over-year, maintaining an industry leading position in China. In the Reporting Period, SMO supported 10 new drug approvals for customers. Clinical CRO enabled our customers to obtain 7 IND approvals.

WuXi Biology: New Modalities Business Drives Growth; WuXi Biology Platform Continues to Generate Downstream Opportunities

Revenue from WuXi Biology reached RMB0.56 billion. Adjusted non-IFRS gross profit margin was 38.5%.

The Company focused on improving capabilities related to new modalities. In the Reporting Period, WuXi Biology revenue from new modalities grew 12.2% year-over-year, contributing 29.2% of WuXi Biology revenue.

The Company further integrated resources of its in vivo pharmacology platform and continued to improve platform capabilities and efficiency.

The Company commenced operations at the Suzhou Guoxiang research platform by the end of March 2024, strengthening new capabilities of in vitro biology and in vivo pharmacology.

In the Reporting Period, WuXi Biology continued to generate downstream opportunities and contributed more than 20% of the Company's new customers.

WuXi ATU: Commercial Projects Gradually Approved, Driving Future Growth

Revenue from WuXi ATU reached RMB0.28 billion. Adjusted non-IFRS gross profit margin was (32.8)%. Mainly due to: the completion of high-margin projects in 2023; the approval of the new TIL product in late February 2024, with an increase in costs associated with talents reserved for commercial manufacturing in advance; and the under-utilization of capacity for other projects.

The Company focused on improving our CTDMO integrated enabling platform and strengthening capabilities and capacity. As of March 31, 2024, we provided development, testing and manufacturing services for 65 projects, including 2 commercial projects, 5 Phase III projects (2 projects in BLA preparation stage), 9 Phase II projects and 49 pre-clinical and Phase I projects, among which, the world's first innovative TIL-based therapy was approved by FDA in the first quarter.

We are preparing for BLA filing to manufacture the LVV used in a commercial CAR-T product. We completed process performance qualification (PPQ) and started post-PPQ manufacturing, expect to file pre-approval submission (PAS) to FDA in the second half of 2024. Moreover, we expect to complete PPQ and file PAS to FDA in the second half of 2024 for a blockbuster commercial CAR-T product.

WuXi DDSU[3]: Supporting Customers to Continue Advancing Pipeline Projects

Revenue from WuXi DDSU reached RMB0.08 billion. Adjusted non-IFRS gross profit margin was 26.9%.

As of March 31, 2024, 3 new drugs developed for our customers obtained NMPA approvals, including 2 for COVID-19 infection treatments and 1 for tumor treatment. We continued to receive royalty income of the approved new drugs from customers. Moreover, 2 new drug candidates are in the NDA review stage.

In the Reporting Period, we supported customers to file INDs for 6 drug candidates and obtain 6 Clinical Trial Approvals (CTAs). Cumulatively, we have submitted 196 new chemical entity IND filings and obtained 175 CTAs for customers, among which 3 projects have obtained NDA approvals, 2 projects are in the NDA review stage, 4 projects are in Phase III, 35 projects are in Phase II, and 71 projects are in Phase I, covering multiple therapeutic areas.

Demand declined significantly, and thus fewer new projects were signed as expected.

This release provides a summary of the results and is not intended to be a comprehensive report. For additional information, please refer to the WuXi AppTec 2024 First Quarterly Results Presentation and 2024 First Quarterly Report disclosed on the Company's official website, as well as the 2024 First Quarterly Report and other relevant announcements published on the websites of the Shanghai Stock Exchange (www.sse.com.cn) and the Stock Exchange of Hong Kong (www.hkexnews.hk), and the designated media for dissemination of the relevant information. Investors are advised to exercise caution and be aware of the investment risks in trading Company shares.

All financial information disclosed in this press release is prepared based on International Financial Reporting Standards (IFRS), in currency of RMB.

The 2024 First Quarterly Report of the Company has not been audited.

https://www.wuxiapptec.com/news/wuxi-news/5746

Xian Janssen Pharmaceutical Ltd.(NYSE: JNJ)

Since bringing the first batch of drugs into China in 1985, Xi'an Janssen has been committed to developing, introducing and producing high-quality drugs and innovative pharmaceutical solutions to meet China's growing medical and health needs. As one of the earliest established multinational pharmaceutical companies and the largest pharmaceutical subsidiary of Johnson & Johnson in China, Xi'an Janssen's products focus on six major disease areas that can bring huge changes to human health: oncology, immunology, infectious diseases and vaccines, neurology Science, Cardiovascular & Metabolism, and Pulmonary Hypertension.

For more than 30 years, we have witnessed and participated in the vigorous development of China's medical and health care. As an active corporate citizen, we have continuously actively sought cooperation in medicine, public health, drug research and development, public welfare practices and sustainable development, and joined hands with people with lofty ideals. Fulfill the commitment to give back to society and strive to contribute social value.

As of 2018, we have offices in 29 cities across the country and nearly 3,000 employees. Based on the company's creed and caring spirit, we have established a sustainable talent training system to help employees achieve diversified value and development.

We believe that only by being patient-centered and combining our dedicated pursuit of science with the health and well-being of patients can we achieve our goal of providing innovative drugs and comprehensive medical solutions to Chinese patients and medical health professionals, and ultimately provide China with The development of the medical and health industry creates endless possibilities.

https://www.xian-janssen.com.cn/about-xian-janssen/company-overview

Johnson & Johnson Reports 2019 Third-Quarter Results.

23/10/2019

For the full release see:

https://johnsonandjohnson.gcs-web.com/static-files/3671f909-a0e9-41c1-b067-290dd786bfe5

ACQ_REF: IS/43186/20240430/CHN/24/11

ACQ_AUTHOR: Associate/Audrey Anak Awie

COPYRIGHT 2024 Acquisdata, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.

LATEST COMPANY NEWS. - Free Online Library (2024)

FAQs

Is there a library version of Newspapers com? ›

Newspapers.com Library Edition is an extensive online database of 3,000+ historical newspapers from the early 1700s into the early 2000s. It contains a diverse blend of well-known regional and local newspapers in the U.S. and other countries.

See Details ›

How can you read newspapers for free? ›

With databases like EBSCOHost and Pro-Quest, library users have free access to top newspaper publications like The New York Times, Wall Street Journal, Los Angeles Times and more. In Pro-Quest, U.S. Major Dailies, you'll find U.S. national and regional newspapers.

See Details ›

Is NewsBank reliable? ›

One of the hallmarks of Access Global NewsBank is NewsBank's commitment to curating content from reputable sources. Every article and publication available on the platform come from vetted newspapers and journals, renowned for their journalistic integrity and accuracy.

Tell Me More ›

Can you get newspapers.com for free? ›

FREE ACCESS at Newspapers.com: About Newspapers.com™

*Access to all papers on Newspapers.com™ will be free until 12 May 2024 at 11:59pm MT. Registration required. After the free access period ends, you will only be able to view all papers using a Newspapers.com™ Publisher Extra subscription. Terms and Conditions apply.

Learn More ›

How to read newspapers online through library? ›

If you're on iOS or Android, download the PressReader app. If you're on a computer, visit the PressReader website. Once on PressReader, click on the “Sign In” text on the top right of the screen to access the sign in options. Click the “Library or Group” button to sign in as a library user.

Know More ›

What is the best free online newspaper? ›

If you're looking to read newspapers online, India First Epaper is a fantastic option. It offers a wide range of newspapers from various regions across India, providing you with diverse news coverage. Simply visit the India First Epaper website and navigate to the section dedicated to newspapers.

Discover More ›

Are there still free newspapers? ›

A wide variety of free newspapers can be found in the United States. These include daily news- papers like the geographic-specific Vail Daily in Colorado and Metro, a tabloid-sized daily that targets commuters in New York City, Philadelphia, and Boston.

Explore More ›

How to access newspaper archives for free? ›

Google News Archive is an extension of Google News. It provides free access to scanned archives of newspapers and links to other newspaper archives on the web, both free and paid. Some of the news archives date back to the 18th century. There is a timeline view available to help you select news from a specific period.

Show Me More ›

Is NewsLibrary.com legit? ›

NewsLibrary.com provides only information from trusted sources, ensuring credible search results. NewsLibrary.com content is derived via publishing partnerships with leading news providers nationwide.

Read On ›

Is PressReader any good? ›

Readers around the globe access PressReader through their local library, and it's easy to see why they love it. After all, PressReader is the world's largest digital newsstand, where library patrons can find complete issues of more than 7,000 newspapers and magazines from more than 120 countries.

Keep Reading ›

How far back does NewsBank go? ›

America's Historical Newspapers makes it easy for students to search and browse hundreds of U.S. newspapers published from 1690 through the 20th Century, including titles from all 50 present states.

Learn More ›

Is there a newspaper com? ›

Newspapers.com is an extensive database that provides online access to historical newspapers from nearly 60 locations in the U.S. and worldwide. The World Collection is a prime resource for genealogy and historical content. For more information about Newspapers.com navigate to the Content Page.

View Details ›

How much does newspaper com cost? ›

In this case you can subscribe directly to Newspapers.com only. They offer 6 month memberships and monthly options – the price is about $8 a month for basic and $20 for plus – with some pretty steep discounts for some 6 month memberships ($45 and $75 respectively).

Is newspapers com owned by ancestry? ›

In 2012, Ancestry spun off its digitized online newspaper components into a standalone service, Newspapers.com.

Read The Full Story ›

What is the difference between newspapers com basic and Publisher Extra? ›

The Basic plan only offers newspaper images that are already out of copyright. To access newer papers, from 1922 or 1963 up through the previous month of the current year, users must pay for the Publisher Extra subscription, which was introduced in 2016 (blog.newspapers.com/introducing-publisher-extra).

Know More ›

LATEST COMPANY NEWS. - Free Online Library (2024)

FAQs

Is there a library version of Newspapers com? ›

How far back does NewsBank go? ›

References